SLC5A2 and type 2 diabetes mellitus: Questions also remain regarding cost-effectiveness in particular patient subgroups, although SGLT2 inhibitors, GLP-1 RAs and DPP-4 inhibitors are generally considered to be cost-effective compared with insulin, thiazolidinediones and sulfonylureas in patients with T2D [106, 107].